101 related articles for article (PubMed ID: 23992112)
21. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
[TBL] [Abstract][Full Text] [Related]
22. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
23. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
24. DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.
Ellingsen C; Hompland T; Galappathi K; Mathiesen B; Rofstad EK
Radiother Oncol; 2014 Feb; 110(2):335-41. PubMed ID: 24231244
[TBL] [Abstract][Full Text] [Related]
25. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
[TBL] [Abstract][Full Text] [Related]
26. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses.
Ng CS; Raunig DL; Jackson EF; Ashton EA; Kelcz F; Kim KB; Kurzrock R; McShane TM
AJR Am J Roentgenol; 2010 Feb; 194(2):W134-40. PubMed ID: 20093564
[TBL] [Abstract][Full Text] [Related]
27. An MRI Method To Map Tumor Hypoxia Using Red Blood Cells Loaded with a pO2-Responsive Gd-Agent.
Di Gregorio E; Ferrauto G; Gianolio E; Lanzardo S; Carrera C; Fedeli F; Aime S
ACS Nano; 2015 Aug; 9(8):8239-48. PubMed ID: 26234938
[TBL] [Abstract][Full Text] [Related]
28. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.
Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S
Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393
[TBL] [Abstract][Full Text] [Related]
29. Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging.
Pinker K; Bogner W; Baltzer P; Gruber S; Bickel H; Brueck B; Trattnig S; Weber M; Dubsky P; Bago-Horvath Z; Bartsch R; Helbich TH
Invest Radiol; 2014 Jun; 49(6):421-30. PubMed ID: 24566292
[TBL] [Abstract][Full Text] [Related]
30. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
31. Detection of prostate cancer in peripheral zone: comparison of MR diffusion tensor imaging, quantitative dynamic contrast-enhanced MRI, and the two techniques combined at 3.0 T.
Li C; Chen M; Li S; Zhao X; Zhang C; Luo X; Zhou C
Acta Radiol; 2014 Mar; 55(2):239-47. PubMed ID: 23892233
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
33. Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent.
Zhou X; Fan X; Mustafi D; Pineda F; Markiewicz E; Zamora M; Sheth D; Olopade OI; Oto A; Karczmar GS
Phys Med; 2021 Jan; 81():31-39. PubMed ID: 33373779
[TBL] [Abstract][Full Text] [Related]
34. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
Hsu YH; Ferl GZ; Ng CM
Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
[TBL] [Abstract][Full Text] [Related]
35. Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance.
Andersen EK; Hole KH; Lund KV; Sundfør K; Kristensen GB; Lyng H; Malinen E
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e485-92. PubMed ID: 22014954
[TBL] [Abstract][Full Text] [Related]
36. Combined diffusion-weighted, blood oxygen level-dependent, and dynamic contrast-enhanced MRI for characterization and differentiation of renal cell carcinoma.
Notohamiprodjo M; Staehler M; Steiner N; Schwab F; Sourbron SP; Michaely HJ; Helck AD; Reiser MF; Nikolaou K
Acad Radiol; 2013 Jun; 20(6):685-93. PubMed ID: 23664397
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
[TBL] [Abstract][Full Text] [Related]
38. Dynamic contrast-enhanced magnetic resonance imaging measurements in renal cell carcinoma: effect of region of interest size and positioning on interobserver and intraobserver variability.
Braunagel M; Radler E; Ingrisch M; Staehler M; Schmid-Tannwald C; Rist C; Nikolaou K; Reiser MF; Notohamiprodjo M
Invest Radiol; 2015 Jan; 50(1):57-66. PubMed ID: 25260094
[TBL] [Abstract][Full Text] [Related]
39. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor.
Bentzen L; Vestergaard-Poulsen P; Nielsen T; Overgaard J; Bjørnerud A; Briley-Saebø K; Horsman MR; Ostergaard L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1208-15. PubMed ID: 15752903
[TBL] [Abstract][Full Text] [Related]
40. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
